To examine the usefulness of CSR monitoring as a predictor of cardiac disease in OSA patients undergoing CPAP treatment. A Case-Control Study

To examine the usefulness of CSR monitoring as a predictor of cardiac disease in OSA patients undergoing CPAP treatment. A Case-Control Study - Efficacy of CSR Remote Monitoring

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042555

Enrollment

700

Registered

2021-01-01

Start date

2020-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep apnea syndrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) OSA patients who received CPAP treatment in our clinic from January 2018 to December 2020. 2) OSA patients with AHI 20 or greater at PSG. 3) Patients who have received informed consent.

Exclusion criteria

Exclusion criteria: 1)Major uncontrolled medical or psychiatric conditions 2)The presence of untreated and diagnosable non-OSA sleep disorders (e.g., restless leg syndrome, insomnia, PLMD). 3)Current shift work

Design outcomes

Primary

Measure	Time frame
Using data from CPAP software downloads, we examined the association between %CSR, CSR variability every 3-7 days, and various respiratory indices and new onset of cerebrovascular or cardiac disease, exacerbation of chronic heart failure, onset or recurrence of atrial fibrillation, and sudden death during sleep. We defined the event-onset group as cases with new onset of cerebrovascular or cardiac disease and sudden death during sleep during the 3-year period 2018-2020, and examined factors influencing these events compared with a control group that did not develop these events in 2020.	—

Measure

Time frame

Using data from CPAP software downloads, we examined the association between %CSR, CSR variability every 3-7 days, and various respiratory indices and new onset of cerebrovascular or cardiac disease, exacerbation of chronic heart failure, onset or recurrence of atrial fibrillation, and sudden death during sleep. We defined the event-onset group as cases with new onset of cerebrovascular or cardiac disease and sudden death during sleep during the 3-year period 2018-2020, and examined factors influencing these events compared with a control group that did not develop these events in 2020.

—

Secondary

Measure	Time frame
The CSR% and CSR variability in the control group were determined. We examined the usefulness of monitoring CSR%, variability, and various respiratory event indices in predicting the onset of events.	—

Countries

Japan

Contacts

Public ContactKIMIMASA SAITO

Medical corporation MSC Mie Sleep Clinic

k1saito@carrot.ocn.ne.jp+81-596-29-1159

Outcome results